Citation Impact
Citing Papers
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
2008 StandoutNobel
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
2022 StandoutNobel
Obesity and Kidney Disease: Hidden Consequences of the Epidemic
2017 Standout
The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells
2011
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
2016 Standout
Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers
2005
Urine markers for detection and surveillance of bladder cancer
2013
Defining the role of NMP22 in bladder cancer surveillance
2007
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
2016 Standout
Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing
2016 Standout
The Role of Tissue Inhibitors of Metalloproteinases in Tumorigenesis and Metastasis
2008
Cancer to bone: a fatal attraction
2011 Standout
The complex interaction between obesity, metabolic syndrome and reproductive axis: A narrative review
2012
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study
2017 Standout
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
2011 StandoutNature
Human prostate cancer risk factors
2004
Hyaluronan: from extracellular glue to pericellular cue
2004 Standout
Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract
2004
The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report
2010 Standout
The human keratins: biology and pathology
2008 Standout
Arrestin Development: Emerging Roles for β-arrestins in Developmental Signaling Pathways
2009 StandoutNobel
Obesity and inflammation: the linking mechanism and the complications
2016 Standout
Emphysematous Pyelonephritis
2000 Standout
Epidemiology of Prostate Cancer
2019 Standout
Role of transforming growth factor-β superfamily signaling pathways in human disease
2008
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?
2009
Chronic kidney disease
2011 Standout
Engineering interferons and interleukins for cancer immunotherapy
2022
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
2013 Standout
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Clinical Use of Interferon‐γ
2009
Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials
2006 Standout
Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses
2003
Diagnosis of urothelial carcinoma from urine
2009
Cytokine patterns in patients with cancer: a systematic review
2013 Standout
Bladder cancer
2016 Standout
Immunity, Inflammation, and Cancer
2010 Standout
Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews
2005 Standout
Infections in Patients with Diabetes Mellitus
1999 Standout
TGF-β and fibrosis in different organs — molecular pathway imprints
2009 Standout
STATs in cancer inflammation and immunity: a leading role for STAT3
2009 Standout
Clinical utility of cytokeratins as tumor markers
2004
Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid–hyaluronidase and BTA‐Stat tests
2002
EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease
2010
The Emerging Hallmarks of Cancer Metabolism
2016 Standout
Urine Markers for Bladder Cancer Surveillance: A Systematic Review
2005
EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction
2013 Standout
P53 as a prognostic marker for bladder cancer: a meta-analysis and review
2005
Recurrence and Progression of Disease in Non–Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy
2009 Standout
AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both
2017 Standout
What We Talk About When We Talk About Fat
2014 Standout
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
2019 Standout
Trial watch: IDO inhibitors in cancer therapy
2014
Properties of mammalian O6-alkylguanine-DNA transferases
1990
Molecular Markers for Bladder Cancer Screening, Early Diagnosis, and Surveillance: The WHO/ICUD Consensus
2014
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
2016 StandoutNobel
EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
2008 Standout
EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013
2013 Standout
Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations
2004 StandoutNobel
QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies
2011 Standout
Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies.
2004 Standout
Natural Innate and Adaptive Immunity to Cancer
2011 Standout
Tumor Markers in the Diagnosis of Primary Bladder Cancer. A Systematic Review
2003
Current Issues in Measurement and Reporting of Urinary Albumin Excretion
2008
Spectrum of gas within the kidney
1987
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
The extracellular matrix at a glance
2010 Standout
CD4+CD25high T Cells Are Enriched in the Tumor and Peripheral Blood of Prostate Cancer Patients
2006
The MicroRNA Spectrum in 12 Body Fluids
2010 Standout
Urinary Biomarkers for Diagnosis of Bladder Cancer
2015
Mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea in human medulloblastoma and rhabdomyosarcoma.
2002 StandoutNobel
The Role of Adiponectin in Cancer: A Review of Current Evidence
2012
p53 Immunohistochemistry as a Prognostic Marker in Bladder Cancer
2000
Androgen Receptor in Prostate Cancer
2004
Interferons, immunity and cancer immunoediting
2006
Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis
2010 Standout
Dual Faces of IFNγ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity
2016
The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta‐analysis, and clinical practice guideline: a systematic review
2015 Standout
Systematic reviews: CRD's guidance for undertaking reviews in health care
2010 Standout
Systematic Reviews of Diagnostic Test Accuracy
2008
Works of A. Giannopoulos being referenced
Serum Adiponectin Concentrations and Tissue Expression of Adiponectin Receptors Are Reduced in Patients with Prostate Cancer: A Case Control Study
2007
Pain during transrectal ultrasonography guided prostate biopsy: a randomized prospective trial comparing periprostatic infiltration with lidocaine with the intrarectal instillation of lidocaine-prilocain cream
2003
Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: Comparison with dna ploidy
1995
Characterization of the human urine proteome by preparative electrophoresis in combination with 2‐DE
2006
Comparative evaluation of the BTAstat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors
2000
Development and validation of a new assay for O6-alkylguanine-DNA-alkyltransferase based on the use of an oligonucleotide substrate, and its application to the measurement of DNA repair activity in extracts of biopsy samples of human urinary bladder mucosa
1989
In vivo effect of the lipido-sterolic extract of Serenoa repens (Permixon) on mast cell accumulation and glandular epithelium trophism in the rat prostate
2002
COMPARATIVE EVALUATION OF THE DIAGNOSTIC PERFORMANCE OF THE BTA STAT TEST, NMP22 AND URINARY BLADDER CANCER ANTIGEN FOR PRIMARY AND RECURRENT BLADDER TUMORS
2001
Immunohistochemical expression of transforming growth factor beta 1 and nm-23 H1 antioncogene in prostate cancer: divergent correlation with clinicopathological parameters.
2001
Unilateral Emphysematous Pyelonephritis
1979
Tissue inhibitor of metalloproteinase-2 as a multifunctional molecule of which the expression is associated with adverse prognosis of patients with urothelial bladder carcinomas.
2003
The immunomodulating effect of interferon-gamma intravesical instillations in preventing bladder cancer recurrence.
2003